Agenus

Agenus ROE

The Return on Equity (ROE) of Agenus (AGEN) as of Oct 17, 2026 is -0.04 %. In the previous year, Return on Equity (ROE) was 69.62 % — a change of -100.06% (lower).

ROE

-0.04 %

YoY

-100.06%

Last updated:

In 2025, Agenus's return on equity (ROE) was -0.04 %, a -100.06% increase from the 69.62 % ROE in the previous year.

The Agenus ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
91.49 USD
Jan 1, 2019
46.54 USD
Jan 1, 2020
85.54 USD
Jan 1, 2021
-49.94 USD
Jan 1, 2022
400.85 USD
Jan 1, 2023
165.63 USD
Jan 1, 2024
69.62 USD
Jan 1, 2025
-0.04 USD
The Agenus ROE history
YEARROEYoY
-0.04 %-100.06%
69.62 %-57.97%
165.63 %-58.68%
400.85 %-902.65%
-49.94 %-158.38%
85.54 %+83.81%
46.54 %-49.13%
91.49 %-42.53%
159.19 %-50.95%
324.58 %-361.23%
-124.25 %-32.68%
-184.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Agenus Stock analysis

What does Agenus do? Agenus Inc, listed under the ticker AGEN, is a biotechnology company based in Lexington, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Agenus Inc has a workforce of 81 employees. It went public through an IPO on February 4, 2000. The company's website is http://agenusbio.com/. Agenus Inc is engaged in the development of technologies aimed at treating cancers and infectious diseases. The company focuses on therapies that harness the immune system to combat cancer. Agenus Inc's activities include the development of antibody discovery platforms, such as Retrocyte Display, SECANT yeast display, and phage display technologies, which are used to create human antibodies. Additionally, the company is involved in the development of vaccine programs, including Prophage, AutoSynVax, and PhosPhoSynVax, as well as saponin-based vaccine adjuvants, notably QS-21 Stimulon. The company's discovery pipeline features checkpoint modulating (CPM) antibodies. Agenus Inc also works with heat shock protein (HSP)-based Prophage vaccine candidates and synthetic vaccine candidates, such as ASV and PSV. The company's headquarters are located in Lexington, Massachusetts, and it maintains a focus on advancing immuno-oncology research and development. Agenus is one of the most popular companies on Eulerpool.

ROE Details

Decoding Agenus's Return on Equity (ROE)

Agenus's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Agenus's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Agenus's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Agenus’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Agenus stock

Return on Equity (ROE) of Agenus is -0.04 % in 2025.

Return on Equity (ROE) of Agenus changed from 69.62 % to -0.04 %, representing a -100.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Agenus since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Agenus with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Agenus

All Key Metrics — Agenus